Atlas Wealth’s abrdn Life Sciences Investors HQL Stock Holding History

Atlas Wealth’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-83,322	Closed	-$1.19M	–	116
2024 Q2	$1.19M	Buy	+83,322	New	+$1.13M	0.14%	97
2023 Q4	–	Sell	-24,969	Closed	-$311K	–	108
2023 Q3	$311K	Buy	24,969 +11,879	+91%	+$156K	0.06%	136
2023 Q2	$177K	Buy	+13,090	New	+$181K	0.03%	179

Other funds holding HQL

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

AIA

Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

SIA

Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Atlas Wealth's HQL Position: Q3 2024 in Review

Atlas Wealth sold out of abrdn Life Sciences Investors (HQL) in Q3 2024, closing a stake of 83,322 shares — an estimated $1.19M sold.

Atlas Wealth first reported a position in HQL in Q2 2023 and held it in 3 quarters. The position peaked at $1.19M in Q2 2024. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2024.

Atlas Wealth reported no remaining abrdn Life Sciences Investors position as of Q3 2024 after selling out during the quarter.
Atlas Wealth sold 83,322 abrdn Life Sciences Investors shares in Q3 2024, an estimated $1.19M.
Atlas Wealth first reported a position in abrdn Life Sciences Investors in Q2 2023 and held it in 3 quarters.
Atlas Wealth's abrdn Life Sciences Investors position peaked at $1.19M in Q2 2024.
74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2024.

Based on Atlas Wealth's 13F filing for Q3 2024, filed 14 Nov 2024.